Drug intelligence / Profile preview

murine CD19 CAR-T cells

Development stage: Phase 1
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Murine CD19 CAR-T cells are an adoptive cell therapy that utilizes genetically engineered T cells to express a chimeric antigen receptor (CAR) derived from a mouse antibody, specifically designed to target the CD19 protein found on B-cells. This therapy is being investigated for the treatment of relapsed or refractory CD19+ B-cell hematological malignancies, including acute lymphoblastic leukemia and B-cell non-Hodgkin's lymphoma. Clinical studies have explored its safety and efficacy, noting its ability to induce complete responses in patients. Comparisons with humanized CD19 CAR-T cells suggest that humanized versions may offer improved proliferation, cytotoxicity, and survival benefits.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on murine CD19 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on murine CD19 CAR-T cells.

Explore the full profile